Protalix BioTherapeutics, Inc.
protalix.comWhat Do They Do?
Sells enzyme replacement therapies for Gaucher and Fabry diseases to pharmaceutical partners and Brazil’s health ministry, and develops treatments for rare diseases.
10-K for FY2025, filed Mar 18, 2026To date, we have successfully developed two commercial products, both of which are enzyme replacement therapies (ERTs): Elelyso®…View ↗
Elelyso, our first commercial product, is our proprietary recombinant form of glucocerebrosidase (GCD), an enzyme naturally found in human…View ↗
Elfabrio, our second commercial product, for the treatment of adult patients with Fabry disease, is our proprietary, chemically modified…View ↗
Our first product, Elelyso, an ERT for the treatment of patients with Gaucher disease, was first approved by the FDA in May 2012 and is now…View ↗
Elfabrio, our second commercial product, an ERT for the treatment of Fabry disease, was approved by the EC for marketing in the EU and by…View ↗
How Do They Make Money?
The company sells drug products to Pfizer, Fiocruz and Chiesi, with payment following delivery. Under the Elfabrio agreements, Chiesi also made upfront payments and development-cost reimbursements and may make milestone payments.
10-K for FY2025, filed Mar 18, 2026Our sales of Elelyso to Pfizer and Fiocruz are made at a fixed price directly to Pfizer and Fiocruz who maintain product in inventory, and…View ↗
Under the terms of the Chiesi Agreements, Chiesi is solely responsible for the global commercialization and medical programs of Elfabrio…View ↗
Under each of the Chiesi Agreements, Chiesi made an upfront payment to Protalix Ltd. of $25.0 million in connection with the execution of…View ↗
The Company recognizes revenues from selling goods at a point in time when control over the product is transferred to customers (upon…View ↗
-
10-K for FY2025, filed Mar 18, 2026
FY2025 revenue by product or service ↗
$52.7M
-
10-K for FY2025, filed Mar 18, 2026
$52.7M ↗
| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
GOODS
Sold outright
10-K for FY2025, filed Mar 18, 2026 |
98%
FY2022: 53%
|
GOODS, FY2025
$51.8M Sources
|
Sold outright |
|
LICENSE AND R&D SERVICES
|
1.8%
FY2022: 47%
|
LICENSE AND R&D SERVICES, FY2025
$942K Sources
|
Who Are Their Customers?
Protalix sells Elelyso directly to Pfizer and Fiocruz, and Elfabrio drug product to Chiesi; Pfizer and Chiesi commercialize their licensed products, while Protalix retains Elelyso distribution rights in Brazil.
10-K for FY2025, filed Mar 18, 2026Elelyso, our first commercial product, is our proprietary recombinant form of glucocerebrosidase (GCD), an enzyme naturally found in human…View ↗
Our sales of Elelyso to Pfizer and Fiocruz are made at a fixed price directly to Pfizer and Fiocruz who maintain product in inventory, and…View ↗
We have partnered with Chiesi for the development and commercialization of Elfabrio for the treatment of Fabry disease through two…View ↗
Under the terms of the Chiesi Agreements, Chiesi is solely responsible for the global commercialization and medical programs of Elfabrio…View ↗
Do Revenues Turn Into Profits?
No. It lost $6.6M in FY2025.
10-K for FY2025, filed Mar 18, 2026
−$5.5MView ↗
10-K for FY2025, filed Mar 18, 2026
−$6.6MView ↗
10-K for FY2025, filed Mar 18, 2026
−$13.6MView ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 12, 2026
$3.8MView ↗
- ▲ +2203%
- vs $164K in Q2 FY2025
10-Q for Q2 FY2026, filed Aug 12, 2026
Open tableView ↗
-
Aug 12, 2026
Reaffirmed full-year revenue guidance
The company reiterated total revenue of $78.0 million to $83.0 million, including a $25.0 million Chiesi milestone.
Sources
8-K, filed Aug 12, 2026
Total revenue in 2026 to range from approximately $78.0 million to $83.0 million including the $25.0 million milestone which the Company…View ↗
Growing. Revenue grew 38% in 4 years, from $38.4M in FY2021 to $52.7M in FY2025, about 8% a year.
Who Do They Compete With?
Competes with Sanofi Genzyme, Takeda, Actelion, Sanofi, Amicus, Sangamo Therapeutics, Amgen, Swedish Orphan Biovitrum, Crucell, Dyadic International, Pfenex, iBio, Medicago, and Eleva Biologics
10-K for FY2025, filed Mar 18, 2026With respect to Gaucher disease, we face competition primarily from two ERTs, Sanofi Genzyme’s Cerezyme and Takeda’s (Shire) Vpriv. In…View ↗
Loading...
